Detalles de la búsqueda
1.
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
J Hepatol
; 78(5): 914-925, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36804402
2.
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
J Pharmacol Exp Ther
; 382(2): 208-222, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764327
3.
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Diabetes Obes Metab
; 23(3): 664-673, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269554
4.
Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Eur J Clin Pharmacol
; 76(10): 1393-1400, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32556539
5.
Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Am J Physiol Endocrinol Metab
; 311(2): E461-70, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27406738
6.
Imeglimin: A Clinical Pharmacology Review.
Clin Pharmacokinet
; 62(10): 1393-1411, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37713097
7.
Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
Clin Drug Investig
; 42(9): 721-732, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35867199
8.
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.
Clin Transl Sci
; 15(4): 1014-1026, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34962074
9.
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Physiol Rep
; 10(5): e15151, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274817
10.
Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Endocrinol Diabetes Metab
; 5(6): e371, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239048
11.
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
Hepatol Commun
; 6(1): 101-119, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34494384
12.
In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.
Mol Pharm
; 8(3): 651-63, 2011 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21438632
13.
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
Clin Pharmacokinet
; 60(4): 485-490, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33169345
14.
Imeglimin preserves islet ß-cell mass in Type 2 diabetic ZDF rats.
Endocrinol Diabetes Metab
; 4(2): e00193, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33855202
15.
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.
PLoS One
; 16(2): e0241651, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33606677
16.
Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity.
Hepatol Commun
; 5(8): 1412-1425, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34430785
17.
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Lancet Gastroenterol Hepatol
; 6(11): 889-902, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34560015
18.
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Cell Rep Med
; 2(12): 100474, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35028615
19.
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Clin Pharmacokinet
; 59(10): 1261-1271, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270440
20.
Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Eur J Drug Metab Pharmacokinet
; 45(6): 725-733, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32860624